Zevra Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Neil F. McFarlane
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1180 Celebration Boulevard Boston FL United States of America 34747
- IPO Date
- Apr 16, 2015
- CIK
- 0001434647
- Website
- zevra.com
- Similar Companies
- Business
- Zevra Therapeutics, Inc. (Nasdaq: ZVRA) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company offers MIPLYFFA (arimoclomol) capsules approved in the U.S. for use in combination with miglustat to treat neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged two years and older; OLPRUVA (sodium phenylbutyrate) for oral suspension approved in the U.S. for treating certain urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS); and receives royalties and milestones from its partner Corium Inc. on AZSTARYS (serdexmethylphenidate and dexmethylphenidate), approved in the U.S. for attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. Zevra maintains a late-stage clinical pipeline targeting additional rare disease indications and operates primarily in the United States with plans for European expansion of MIPLYFFA. Founded in 2006 and headquartered in Celebration, Florida, Zevra previously operated as KemPharm, Inc. before rebranding. The company targets patients with rare neurological, metabolic, and neuropsychiatric conditions through data-driven development, regulatory strategies, and commercialization efforts in collaboration with physicians, advocacy groups, and patient communities. Recent developments include the 2023 acquisition of Acer Therapeutics, which added OLPRUVA and expanded clinical assets such as Edsivo for vascular Ehlers-Danlos syndrome; U.S. FDA approval of MIPLYFFA in 2024 with ongoing commercial launches showing strong prescription uptake and market access progress; and the February 2025 sale of a Rare Pediatric Disease Priority Review Voucher for $150 million in non-dilutive proceeds to support pipeline advancement and launches. In May 2025, Zevra partnered with Alucio to deploy the Beacon platform for enhancing medical affairs scientific exchange amid its product launches. Zevra reports sequential revenue growth from MIPLYFFA and OLPRUVA, with U.S. market access reaching 66% for MIPLYFFA and European opportunities under evaluation.
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy” by Analysts
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Why Zevra Therapeutics Stock Zoomed 21% Higher Today
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer